Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KIORA PHARMACEUTICALS INC Director's Dealing 2020

Aug 5, 2020

35256_dirs_2020-08-05_d520925a-d17f-468a-bb85-b3792c1da4ec.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2020-08-04

Reporting Person: Romano Sarah (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-08-04 Common Stock F 95 $4.11 Disposed 26111 Direct

Footnotes

F1: Sale of shares to cover taxes due on restricted stock that vested on 08/01/2020.